Nirsevimab slashes RSV hospitalizations in infants by 78% in real-world study
Sanatate
By Dr. Priyom Bose, Ph.D. Reviewed by Benedette Cuffari, M.Sc. May 8 2025 Real-world data from Madrid hospitals show dramatic declines in infant ICU stays, hospital days, and RSV-related admissions after nirsevimab immunization campaign. Study: Impact of Nirsevimab on RSV and Non-RSV Severe Respiratory Infections in Hospitalized Infants . Image Credit: Gorodenkoff / Shutterstock.com A recent Influenza and Other Respiratory Viruses study compares the clinical and virological characteristics of
din zilele anterioare